Image-based Detection of Mismatch Repair Deficiency in Prostate Cancer Using Transfer Learning
Lucas J. Liu, Ruth Etzioni, Haoyue Zhang, Erolcan Sayar, Helen Richards, Zhijun Chen, Heather Kirkham, Azra Ajkunic, Sajida Hassan, Eric Q. Konnick, Evan Y. Yu, Daniel W. Lin, Michael T. Schweizer, Jonathan L. Wright, Ruth F. Dumpit, Gavin Ha, Colm Morrissey, Peter S. Nelson, Mark D. Linch, Colin C. Pritchard, Michael C. Haffner, Stephanie A. HarmonAbstract
Purpose/Background: Tumors with microsatellite instability high/mismatch repair-deficient (MSI-H/dMMR) exhibit distinct biological features and are associated with Lynch syndrome. Current approaches for detecting MSI-H/dMMR status rely on immunohistochemistry or molecular assays. Recent advances in digital pathology have enabled the extraction of clinically relevant molecular tumor features from routine hematoxylin and eosin (H&E)–stained diagnostic slides. Image-based deep learning approaches have the potential to screen for MSI-H/dMMR at scale in tumor types such as localized prostate cancer, in which MSI-H/dMMR is so rare that traditional testing is not routinely performed. Experimental Design: We developed and validated PathStage-MSI, a multi-stage transfer learning framework to predict MSI-H/dMMR status from H&E-stained slides. The model was trained and validated on 984 standard-of-care whole slide images (n = 906 patients) from three international clinical prostate cancer cohorts with matched H&E images and genomic data. To assess model generalizability and stability, we additionally evaluated PathStage-MSI in an independent metastatic prostate cancer cohort comprising 85 WSIs from 29 patients. Results: PathStage-MSI achieved the area under the receiver operating characteristic curve (AUROC) of 0.89 [0.79 - 0.96] and 0.91 [0.81 - 0.98] in two internal hold-out validation cohorts, 0.75 [0.57 - 0.88] and 0.81 [0.66 - 0.94] in two independent external validation cohorts. Conclusions: PathStage-MSI is a deep learning–based image analysis framework for detecting MSI-H/dMMR prostate cancer directly from routine histopathology. By enabling efficient pre-screening for this rare molecular subtype, it has the potential to improve patient identification for precision therapies and appropriate germline genetic testing.